Trisnorsqualene Alcohol

Trisnorsqualene Alcohol

SCHEMBL2587282

CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCCO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SQLE Q14534 8/20 1.00
KMT2A Q03164 3/20 0.74
MAPT P10636 2/20 0.65
MEN1 O00255 2/20 0.65
CYP3A4 P08684 2/20 0.65
ALOX15 P16050 2/20 0.65
ALDH1A1 P00352 1/20 0.65
UGT1A1 P22309 1/20 0.65
ICMT O60725 1/20 0.56
KDM4E B2RXH2 1/20 0.53
FNTA P49354 1/20 0.50
FNTB P49356 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trisnorsqualene Alcohol SCHEMBL2587286 1.00 SQLE (1.00) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL8425939 1.00 SQLE (1.00) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL20449625 1.00 SQLE (1.00) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL16451625 1.00 SQLE (1.00) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL5143580 0.92 SQLE (0.96) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL24940711 0.89 SQLE (0.80) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL16221426 0.89 SQLE (0.80) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL24940909 0.89 SQLE (0.80) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL8625008 0.89 SQLE (0.80) SQLEKMT2AMAPTMEN1CYP3A4
SCHEMBL24940873 0.89 SQLE (0.80) SQLEKMT2AMAPTMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0521103-B1 NOVEL CYCLOPROPYL SQUALENE DERIVATIVES AND THEIR USE AS INHIBITORS OF CHOLESTEROL SYNTHESIS MERRELL DOW PHARMA (US) 1995-09-27 EP claimed
EP-3733658-B1 PRENYLATED BENZOPYRANES AS PPAR AGONISTS UNIV VALENCIA (ES) 2023-02-22 EP disclosed
EP-2649084-B1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION ROUSSY INST GUSTAVE (FR) 2017-02-22 EP disclosed
US-20160333038-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INSTITUT GUSTAVE ROUSSY (FR) 2016-11-17 US disclosed
US-20160333038-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INSTITUT GUSTAVE ROUSSY (FR) 2016-11-17 US disclosed
US-9428530-B2 Derivatives of oxazaphosphorines that are pre-activated, use and method of preparation INSTITUT GUSTAVE ROUSSY (FR) 2016-08-30 US disclosed
US-9428530-B2 Derivatives of oxazaphosphorines that are pre-activated, use and method of preparation INSTITUT GUSTAVE ROUSSY (FR) 2016-08-30 US disclosed
US-9295630-B2 Vitamin C complexes CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-03-29 US disclosed
US-9295630-B2 Vitamin C complexes CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-03-29 US disclosed
US-20150315220-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INSTITUT GUSTAVE ROUSSY (FR) 2015-11-05 US disclosed
US-20130261088-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INSTITUT GUSTAVE ROUSSY (FR) 2013-10-03 US disclosed
US-20130261088-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INSTITUT GUSTAVE ROUSSY (FR) 2013-10-03 US disclosed
WO-2013136294-A1 VITAMIN C COMPLEXES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-09-19 WO disclosed
WO-2012076824-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INSTITUT GUSTAVE ROUSSY (FR) 2012-06-14 WO disclosed
US-20110269731-A1 NANOPARTICLES OF BETA-LACTAM DERIVATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-11-03 US disclosed
US-20110269830-A1 STATIN NANOPARTICLES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-11-03 US disclosed
WO-2010049899-A1 NANOPARTICLES OF BETA-LACTAM DERIVATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-05-06 WO disclosed
EP-0521103-B1 NOVEL CYCLOPROPYL SQUALENE DERIVATIVES AND THEIR USE AS INHIBITORS OF CHOLESTEROL SYNTHESIS MERRELL DOW PHARMA (US) 1995-09-27 EP disclosed
US-5102915-A Cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis MERRELL DOW PHARMACEUTICALS INC. (US) 1992-04-07 US disclosed
US-5051534-A For treatment of vascular disease MERRELL DOW PHARMACEUTICALS INC. (US) 1991-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333038-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INPP5B, TYMP, ENTPD5 SQLE 4094/4885KMT2A 2740/4885MAPT 4487/4885
US-20150315220-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INPP5B, TYMP, ENTPD5 SQLE 4094/4885KMT2A 2740/4885MAPT 4487/4885
US-20110269830-A1 STATIN NANOPARTICLES HMGCR, PCSK9, CETP SQLE 281/4885KMT2A 325/4885MAPT 434/4885
US-20110269731-A1 NANOPARTICLES OF BETA-LACTAM DERIVATIVES BACE1, BBOX1, PTMS SQLE 1001/4885KMT2A 466/4885MAPT 897/4885
US-20130261088-A1 NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION INPP5B, TYMP, ENTPD5 SQLE 4094/4885KMT2A 2740/4885MAPT 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.